Guardant Health (NASDAQ:GH) Price Target Raised to $130.00 at JPMorgan Chase & Co.

Guardant Health (NASDAQ:GH) had its price target boosted by JPMorgan Chase & Co. from $120.00 to $130.00 in a report published on Friday,Benzinga reports. They currently have an overweight rating on the stock.

Several other equities analysts have also recently issued reports on GH. Barclays restated an “overweight” rating and issued a $130.00 price target on shares of Guardant Health in a research report on Friday. Wells Fargo & Company lifted their target price on Guardant Health from $120.00 to $125.00 and gave the company an “overweight” rating in a research note on Friday. Canaccord Genuity Group upped their price target on Guardant Health from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a report on Thursday, January 22nd. Finally, Morgan Stanley boosted their price objective on shares of Guardant Health from $105.00 to $130.00 and gave the company an “overweight” rating in a research note on Monday, December 1st. Twenty-one analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Guardant Health presently has an average rating of “Moderate Buy” and an average price target of $117.43.

Guardant Health Trading Down 3.1%

Shares of GH opened at $103.10 on Friday. The company’s 50 day simple moving average is $106.69 and its 200-day simple moving average is $85.94. The firm has a market cap of $12.99 billion, a PE ratio of -31.15 and a beta of 1.63. Guardant Health has a 12-month low of $34.88 and a 12-month high of $120.74.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The company had revenue of $281.27 million for the quarter, compared to analysts’ expectations of $269.74 million. Guardant Health’s revenue for the quarter was up 39.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.62) EPS. As a group, equities research analysts forecast that Guardant Health will post -2.9 EPS for the current fiscal year.

Insider Transactions at Guardant Health

In other news, insider Chris Freeman sold 31,452 shares of the company’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $103.07, for a total transaction of $3,241,757.64. Following the transaction, the insider directly owned 25,987 shares of the company’s stock, valued at $2,678,480.09. This represents a 54.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Terilyn J. Monroe sold 55,167 shares of the firm’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $105.97, for a total transaction of $5,846,046.99. Following the completion of the sale, the insider owned 20,920 shares of the company’s stock, valued at $2,216,892.40. This trade represents a 72.51% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 434,511 shares of company stock valued at $45,580,887 in the last three months. Insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in shares of Guardant Health by 2.1% during the 4th quarter. Vanguard Group Inc. now owns 12,160,768 shares of the company’s stock valued at $1,242,101,000 after acquiring an additional 251,939 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Guardant Health by 33.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock valued at $575,670,000 after purchasing an additional 1,414,441 shares in the last quarter. Baillie Gifford & Co. raised its holdings in Guardant Health by 6.6% during the third quarter. Baillie Gifford & Co. now owns 5,127,692 shares of the company’s stock worth $320,378,000 after purchasing an additional 317,906 shares during the last quarter. Invesco Ltd. boosted its position in Guardant Health by 27.3% during the second quarter. Invesco Ltd. now owns 3,558,501 shares of the company’s stock worth $185,184,000 after purchasing an additional 763,834 shares in the last quarter. Finally, Franklin Resources Inc. grew its holdings in Guardant Health by 14.9% in the fourth quarter. Franklin Resources Inc. now owns 3,361,547 shares of the company’s stock valued at $343,348,000 after purchasing an additional 435,232 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Guardant Health

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Multiple brokerages raised price targets and maintained buy/overweight ratings (Leerink to $180, JPMorgan to $130, Wells Fargo to $125, BTIG to $145, Canaccord to $135), signaling analyst confidence in upside from current levels. Analyst Raises Coverage
• Positive Sentiment: Q4 revenue beat and strong growth: Guardant reported $281.3M in Q4 revenue, +39% YoY and above consensus; management issued FY2026 revenue guidance around $1.3B, above Street expectations — a growth signal for core oncology testing. Press Release
• Positive Sentiment: Research coverage expansion: Robert W. Baird initiated coverage, which can broaden institutional interest and trading liquidity. Coverage Start
• Neutral Sentiment: Conference call and transcript available — provides detail on cadence of test volume, reimbursement progress and product roadmap; useful for digging into guidance assumptions. Earnings Transcript
• Neutral Sentiment: Market materials (slide deck, press release) posted for investors to verify segment trends and margin assumptions. Slide Deck / Press Release
• Neutral Sentiment: Short-interest data flagged a “significant increase” entry but shows 0 shares / NaN in the feed — the published data appears inconsistent, so short-interest impact is unclear. Short Interest Note
• Negative Sentiment: EPS miss: GAAP loss of ($0.50) vs. consensus (~($0.43)), which disappointed some investors despite revenue upside and may have pressured the stock near the close. Earnings Reaction
• Negative Sentiment: Management left EPS guidance effectively blank in the release (revenue guidance given but no numeric EPS target), which can create uncertainty around near-term profitability expectations. Guidance Details

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.